Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Kääb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzenbichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Rizas KD, Massberg S, Bantkowiak M, Baur G, Baylacher M, Beaucamp M, Berger M, Besch L, Brunner S, Budweiser S, Bugger H, Coletti R, Dorwarth U, Egresits J, Eiffener E, Faul C, Finkenstedt A, Gatos K, Gauchel N, Gindele F, Grander W, Gunschl M, Hartig F, Hecht M, Heer T, Heger L, Hentrich M, Horvath L, Keta D, Kiechl S, Kirchmaier R, Klein A, Klemm M, Kolesnik E, König A, Kossmann HC, Kropacek J, Lanser L, Lother A, Löw A, Mahabadi AA, Malleier S, Mayer G, Müller C, Müller-Wieland D, Nagel B, Neuwirt H, Olivier C, Raunegger T, Reindl M, Reinstadler S, Riesinger L, Schäffner M, Schier J, Schock J, Schönherr P, Schulz M, Schütz T, Schwarz J, Siebmaier J, Siry M, Spaur A, Sturm W, Tessadri K, Theurl F, Theurl M, Thommes L, Tiller C, Toifl M, Totzeck M, von zur Mühlen H, Vonderlin N, Wakili R, Wendtner C, Wenner F, Wimmert-Roidl D, Zabernigg A (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 9
Pages Range: 863-872
Journal Issue: 8
DOI: 10.1016/S2213-2600(21)00214-9
Background: SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme 2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed to test our hypothesis that discontinuation of chronic treatment with ACE-inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) mitigates the course o\f recent-onset COVID-19. Methods: ACEI-COVID was a parallel group, randomised, controlled, open-label trial done at 35 centres in Austria and Germany. Patients aged 18 years and older were enrolled if they presented with recent symptomatic SARS-CoV-2 infection and were chronically treated with ACEIs or ARBs. Patients were randomly assigned 1:1 to discontinuation or continuation of RAS inhibition for 30 days. Primary outcome was the maximum sequential organ failure assessment (SOFA) score within 30 days, where death was scored with the maximum achievable SOFA score. Secondary endpoints were area under the death-adjusted SOFA score (AUC
APA:
Bauer, A., Schreinlechner, M., Sappler, N., Dolejsi, T., Tilg, H., Aulinger, B.A.,... Zabernigg, A. (2021). Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. The Lancet Respiratory Medicine, 9(8), 863-872. https://doi.org/10.1016/S2213-2600(21)00214-9
MLA:
Bauer, Axel, et al. "Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial." The Lancet Respiratory Medicine 9.8 (2021): 863-872.
BibTeX: Download